Pediatric Invasive Aspergillosis

Rachel L. Wattier * and Lynn Ramirez-Avila

Department of Pediatrics, Division of Infectious Diseases and Global Health, University of California-San Francisco, 550 16th St, 4th Floor, Box 0434, San Francisco, CA 94143, USA; lynn.ramirez@ucsf.edu

* Correspondence: rachel.wattier@ucsf.edu; Tel.: +1-415-514-0509; Fax: +1-415-885-7690

Academic Editor: William J. Steinbach
Received: 30 April 2016; Accepted: 8 June 2016; Published: 13 June 2016

Abstract: Invasive aspergillosis (IA) is a disease of increasing importance in pediatrics due to growth of the immunocompromised populations at risk and improvements in long-term survival for many of these groups. While general principles of diagnosis and therapy apply similarly across the age spectrum, there are unique considerations for clinicians who care for children and adolescents with IA. This review will highlight important differences in the epidemiology, clinical manifestations, diagnosis, and therapy of pediatric IA.

Keywords: aspergillosis; pediatric; antifungal

1. Introduction

Invasive aspergillosis (IA) is one of the most common and serious infectious complications occurring in immunocompromised children. The incidence of IA appears to be increasing in children as it has in adults [1–5]. Significant advances have occurred in the diagnosis and therapy of IA in the last 15 years, and more recent studies indicate that clinical outcomes have improved during this time period [6,7]. However, treatment success and long-term survival after IA diagnosis remain suboptimal.

The evidence that informs care for children with IA is largely extrapolated from adult studies or based on small non-comparative pediatric studies, predominantly including children with malignancy and/or hematopoietic stem cell transplant (HSCT) recipients. This review will describe the known differences in epidemiology, clinical manifestations, diagnosis and therapy of pediatric IA, and will highlight areas of opportunity for further research.

2. Epidemiology

2.1. Incidence and Vulnerable Populations

The population-based incidence of IA in children is unknown and likely varies across healthcare settings and internationally. According to data from the Kids’ Inpatient Database, a representative dataset of inpatient hospitalizations in the United States, the annual incidence of IA was 437 cases/100,000 (0.4%) hospitalized immunocompromised children in the year 2000 [8]. Among the groups with highest incidence of IA are children severely immunocompromised due to allogeneic HSCT (annual incidence 4.5%), therapy for hematologic malignancies, especially acute myelogenous leukemia (AML; annual incidence 4%), and those with primary immunodeficiencies, particularly chronic granulomatous disease (CGD) (annual incidence 6.5%) [8]. Other populations susceptible to IA include children undergoing solid organ transplantation (SOT) (annual incidence 0.3%), autologous HSCT (annual incidence 0.3%), chemotherapy for solid tumor malignancy (annual incidence 0.1%), and those with advanced acquired immune deficiency syndrome or certain non-malignant hematologic disorders such as bone marrow failure syndromes or hemophagocytic lymphohistiocytosis [6,8–11].
Additionally, IA has been reported in children with systemic lupus erythematosus receiving high dose corticosteroids and other intensive immunosuppression, and has also rarely been reported in preterm neonates [12,13]. The major predisposing risk factors for IA are similar in adults and children (Table 1), except that risk factors within pediatric SOT recipients are poorly characterized due to limited studies.

Table 1. Identified Risk Factors for Invasive Aspergillosis in Children.

| Risk Factor Comments | Specific to Multiple Groups |
|----------------------|-----------------------------|
| Prolonged and severe neutropenia [6,10,14] |
| High dose corticosteroids [6,10,14] |
| Other immunosuppression [6,10,14] |

| Risk Factor Comments | Specific to Children with Malignancy |
|----------------------|--------------------------------------|
| Acute myelogenous leukemia (vs. other malignancies) [11,15] |
| Majority of episodes are diagnosed during intensive phases of therapy [15] |

| Risk Factor Comments | Specific to HSCT a Recipients |
|----------------------|-----------------------------|
| Allogeneic transplant (vs. autologous) [8,10,11,16] |
| Unrelated donor (vs. related donor) [10,11,16] |
| Cord blood transplant (vs. other stem cell source) [16] |
| Graft versus host disease [8,10,11,16] |

| Risk Factor Comments | Specific to SOT b Recipients |
|----------------------|------------------------------|
| Lung transplantation (vs. other organ transplants) [4,8,10,11] |
| Other risk factors related to SOT are poorly characterized in children |

| Risk Factor Comments | Specific to Primary Immunodeficiencies |
|----------------------|---------------------------------------|
| Chronic granulomatous disease [17] |
| Higher risk in lower quartiles of superoxide production [17] |
| Hyper-IgE syndrome [18] |
| Risk associated with pneumatoceles following bacterial pneumonias [18] |
| Other severe defects of phagocyte and/or cellular immunity |
| e.g. Severe combined immunodeficiency, Wiskott-Aldrich syndrome [6,10,19] |

a Hematopoietic stem cell transplant; b Solid organ transplant.

2.2. Causative Species

The major causative species of IA are similar in children and adults, with multicenter studies reporting *Aspergillus fumigatus* as the most commonly identified species, responsible for 53% of cases in the largest pediatric series, followed by *A. flavus* [6,10,20]. Possibly due to differences in local epidemiology, some single centers have reported a predominance of *A. flavus* causing invasive disease in children [14,21,22]. This may also be due changes in clinical presentation of pediatric IA over time, since *A. flavus* is associated with primary cutaneous disease which was a common clinical presentation in early case series [23]. Other commonly reported species in children include *A. niger* and *A. terreus* [6,10,22].

2.3. Clinical Outcomes

Although estimates of mortality for children with IA are difficult to compare due to variable timing of outcome assessment, there have been apparent improvements in mortality over the past 15 years. A systematic review from 1995 to 1999 reported a 68% case-fatality rate for IA in patients under 20 years old [24]. Among 66 pediatric patients with cancer and IA diagnosed from 1962 to 1996, 85% died within one year following IA diagnosis [14]. In the largest multi-center study of children with IA, 52.5%
of patients diagnosed between 2000 and 2005 died during therapy [10]. More recent pediatric cohort studies that have transitioned to earlier outcome assessments at 12 weeks following diagnosis report lower mortality rates of approximately 30% [5,6,25]. Long term survival of children with IA at a single oncology center improved from 12.5% during 1986–2000 to 58% during 2001–2010 [7,26]. A similar improvement in mortality has been observed in adults with IA [20]. Although this improvement is encouraging, 30% short-term mortality is suboptimal, and IA is associated with other adverse outcomes including prolonged hospitalization, increased hospitalization costs, and interruption in therapy for malignancy [5,8,15].

Risk for poor outcomes among children with IA is driven primarily by host immune status and burden of infection. Children who developed IA in the context of allogeneic HSCT in one study had 6-fold greater odds of death during therapy, compared to those with other underlying conditions [10]. Among children with IA in the context of malignancy, a longer duration of neutropenia following IA diagnosis is associated with increased mortality [27]. Disseminated Aspergillus infection has been associated with increased mortality, and non-pulmonary primary sites, such as cutaneous disease, have been associated with better outcomes [14]. Surgical treatment, though not consistently reported across studies, has been associated with improved survival [10].

3. Clinical Manifestations and Diagnosis

3.1. Clinical Manifestations

Similarly to adults, the lungs are the most commonly affected organ in pediatric IA [3,6,10,11,14,20,21,26,28–31]. In a review of 139 pediatric IA cases, 80% of children had pulmonary disease, 14% cutaneous, 13% sinus, 8% cerebral, and 4% tracheobronchitis [10]. Although earlier pediatric studies suggested that cutaneous IA is more common in children than adults [21], more recent studies report lower rates of 14%–20%; this is thought to be due in part to the increasing use of central over peripheral venous catheters in pediatric oncology patients [3,10,14]. Cutaneous IA can be primary from direct inoculation or secondary due to hematogenous dissemination from another site [32]. Several case reports describe primary cutaneous IA in preterm neonates [32–34].

Disseminated infection, defined as disease occurring in ≥2 sites, has been reported in 10.5% to 38% of children with IA and can be due to hematogenous or contiguous spread [3,7,10,14,21,28]. Aspergillus can be locally invasive, with spread from the lung to the pleura, chest wall, and heart, or from the sinus to the central nervous system (CNS). Although no known studies have been performed, some authors suggest screening children with pulmonary IA for CNS involvement given the high mortality, late appearance of symptoms, and impact on treatment [35]. Uncommon sites of IA include the eye [20], head and neck including otitis media and mastoiditis [26], thyroid [36], and gastrointestinal including liver [3,21,31], heart including endocarditis [37] and pericarditis [26], and bone [14,38].

Although some patients with IA present with isolated fever, the clinical manifestations vary depending on which organ system is involved [14]. Fever is common across all presentations. Patients with pulmonary IA can present with cough, dyspnea, hemoptysis/hemorrhage, hypoxia, and pleuritic symptoms [14,28,29]. Cutaneous IA manifestations can be nonspecific and include erythematous plaques, papules, nodules, pustules, blisters, ecchymosis, and eschar formation, often at sites of prior trauma including intravenous catheter and tape sites [14,21,32]. Facial pain, nasal congestion and discharge, visual changes, and headache have been reported in patients with sinus involvement [11,14,39]. CNS IA can present with changes in mental status, visual disturbances, seizures, and focal neurologic deficits [14].

Atypical presentations without fever also occur [11]. It is also reported that up to 33% of patients with CGD who develop IA are asymptomatic and only 20% are febrile [30]. Patients with CGD, especially those infected with A. nidulans, can develop local extension to the pleura, chest wall, and vertebrae [30]. Unlike neutropenic patients who can suffer from extensive fungal angioinvasion with hematogenous dissemination, IA may cause more locally invasive disease in CGD patients.
due to an ongoing and ineffective neutrophilic inflammatory response with persistent hyphae [30]. Patients with hyper-IgE syndrome can present with fungal superinfection of pneumatoceles resulting in aspergillomas and subsequent risk for invasion to the lung parenchyma or disseminated disease [30].

3.2. Diagnostic Methods

Although prompt IA diagnosis is important given the high morbidity and mortality associated with this infection, existing modalities, including microbiology, pathology, fungal biomarkers, and radiology, have limitations. With currently available diagnostic methods, many children with suspected invasive mold infections do not have an identified pathogen, and are treated empirically [40]. The median time from onset of symptoms to diagnosis was 11 days (range 0–69 days) in one cohort, reflecting challenges in establishing a diagnosis with currently available methods [14]. Establishment of an optimal diagnostic approach is limited by few pediatric IA diagnostic studies, and inconsistent application of the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) classifications of proven and probable IA across different studies [41,42]. Further studies in high-risk pediatric patients are needed to establish the ideal timing, frequency, and combination of tests that result in earlier diagnosis.

3.2.1. Culture and Histopathology

Although culture from a sterile site and histopathologic evidence of tissue invasion remain the gold standard for diagnosis of IA, invasive procedures are needed to obtain samples and the diagnostic yield is low. In a pediatric cohort of 193 HSCT patients with fever, respiratory distress, or radiographic findings concerning for an invasive fungal infection (IFI), only 40% of the 101 bronchoalveolar lavages (BAL) performed were diagnostic, all for an infectious etiology, though 94% of the 19 lung biopsies performed yielded a diagnosis [43]. Furthermore, Aspergillus is rarely recovered from blood cultures [3,10,20]. Although the yield is low, positive cultures from affected sites are important because they identify the organism and provide antifungal susceptibilities in this era of emerging resistance even to first-line therapy [44]. Given the low yield of cultures and the morbidity and mortality of invasive procedures, the diagnosis of IA in many patients relies on indirect diagnostics including fungal markers and radiology.

3.2.2. Galactomannan Antigen

Galactomannan is a polysaccharide in the Aspergillus cell wall that is released during fungal growth and can be measured using an enzyme immunoassay. The limited studies evaluating the use of serum galactomannan in children are heterogeneous; some of the studies are single center, focus on those with malignancies and HSCT, use different definitions for IA, antifungal prophylaxis regimens, and galactomannan positivity cut-offs [31,45–52]. Serum galactomannan for prospective screening of high risk patients and diagnosing IA has been studied mostly in immunocompromised adults [45,53–56]. The sensitivity and specificity of serum galactomannan for the diagnosis of IA in children is similar to adults (Table 2) [55,57]. Although earlier studies reported higher false positivity rates in children than adults [58], more recently, the false positive rate in a pediatric cohort was 5.2% [47]. Preterm neonates have a false positive galactomannan rate as high as 83% [59]. The cause of the high false positive rates in this population are not known but could be secondary to cross-reactivity with Bifidobacterium spp. that is a normal part of the neonatal GI flora and present in formula milk [59–61].
Table 2. Fungal Biomarkers for Diagnosis of Invasive Aspergillosis.

| Biomarker Attribute | Galactomannan Antigen (%; 95% CI) | 1,3-β-D-glucan (%; 95% CI) |
|---------------------|----------------------------------|---------------------------|
| **Performance in Serum** |                                  |                           |
| Sensitivity—Adult 5 [55,62] | 78% (70%–85%)                   | 62% (48%–73%)             |
| Sensitivity—Pediatric b [55] | 84% (66%–93%)                   | Unknown                   |
| Specificity—Adult 5 [55,62] | 85% (78%–91%)                   | 91% (83%–95%)             |
| Specificity—Pediatric b [55] | 88% (60%–97%)                   | Unknown—likely less than adult |

| Causes of False Positive Result |                  |
|---------------------------------|------------------|
| Galactomannan                   |                  |
| Piperacillin-tazobactam, other beta lactam antibiotics, Plasmalyte, *Fusarium* spp., *Histoplasma capsulatum*, *Penicillium* spp. [45,60,63,64] |
| Ampicillin-sulbactam, piperacillin-tazobactam, intravenous immunoglobulin, albumin, certain hemodialysis filters, bacteremia [65–67] |

| **Performance in BAL ț Fluid** |                  |
|---------------------------------|------------------|
| Sensitivity—Adult 6 [68]        | 86% n/a ț        |
| Sensitivity—Pediatric ț [69]    | 78% n/a          |
| Specificity—Adult 6 [68]        | 91% n/a          |
| Specificity—Pediatric ț [69]    | 92% n/a          |

5 Positivity cut-off ≥0.5 optical density index (ODI); 6 Subanalysis of 7 pediatric studies within a meta-analysis; 5 studies used a positivity cut-off ≥0.5 ODI, 1 a cut-off ≥1.5 ODI, one did not report cut-off; ț BAL; bronchoalveolar lavage; ș Positivity cut-off ≥0.8 ODI; t Positive cut-off ≥0.98 ODI; ț Not applicable, test not performed on BAL fluid.

Although galactomannan increases with higher infectious burdens [70], it can have reduced sensitivity early in the infection and if the patient is receiving anti-mold therapy [70]. Lower galactomannan sensitivity and specificity has been reported in SOT patients [53]. Possibly due to the lack of angioinvasion, serum galactomannan has reduced sensitivity in patients with CGD [30,71]. In addition to screening and diagnosis, serum galactomannan has been studied as a predictor of clinical response and survival for patients with IA [72–75].

Galactomannan testing can also be performed on BAL fluid, cerebrospinal fluid (CSF), and urine. BAL galactomannan may be a helpful adjunct for the early diagnosis of IA though cut-off values for positivity have not been firmly established [69,76]. In a retrospective pediatric cohort of immunocompromised and immunocompetent patients, a BAL galactomannan cut-off of ≥0.98 optical density index (ODI) resulted in a sensitivity of proven or probable IA of 78% and specificity of 92% [69]. This BAL cutoff when combined with a serum galactomannan of ≥0.5 ODI yielded a sensitivity of 89% and specificity of 90% for proven or probable IA [69].

Few studies have assessed the utility of CSF galactomannan for the diagnosis of CNS IA and specific cut-off values for positivity have not been established. A recent study of pediatric and adult patients with CNS IA reported a CSF galactomannan sensitivity of 88% and specificity of 96% when using a cut-off of ≥1 ODI [77]. Urine galactomannan has also been studied in children though is associated with high false positive rates [47].

3.2.3. Beta-D-Glucan

1,3-β-D-glucan (BDG) is a nonspecific cell wall component of many fungal pathogens including *Aspergillus*. A number of adult studies have assessed the performance of BDG in the diagnosis of IFI and specifically IA (Table 2) [62,78,79]. BDG for the diagnosis of IFI in children is limited to a few case reports and studies [46,67,80–82]. It has been difficult to establish an optimal positive cut-off for children because they have higher baseline levels than adults [83] and levels can be affected by colonization with *Candida* spp., among other causes of false positivity (Table 2) [84].

3.2.4. Molecular Diagnostics

*Aspergillus* polymerase chain reaction (PCR) diagnostics are promising for pediatric IA. In a meta-analysis, the sensitivity of the blood *Aspergillus* PCR ranged from 84%–88% and the specificity
from 75% to 76% [85]; the sensitivity of the BAL *Aspergillus* PCR ranged from 77% to 80% and specificity from 94% to 95% [85]. Fewer studies have assessed *Aspergillus* serum and BAL PCR for screening and diagnosis of IA in children [46,86–90]. Another emerging area is serum and BAL molecular diagnostics for identification of the *Aspergillus* species and the most common mutations that confer azole resistance [91,92]. *Aspergillus* PCR from the CSF [93], pleural fluid, fresh [94] and formalin-fixed paraffin-embedded tissue [95] has also been studied for the diagnosis of IA.

3.2.5. Emerging Diagnostics

Given the limitations of established diagnostic methods, further investigation has attempted to identify additional non-invasive methods to diagnose IA in early stages. Different fungal organisms causing pulmonary infection are associated with characteristic profiles of volatile secondary metabolites that can be detected in exhaled breath [96]. A recent study showed 94% sensitivity (95% CI, 81%–98%) and 93% specificity (95% CI, 79%–98%) for a combination of exhaled metabolites to identify proven or probable pulmonary IA in a cohort of adults with suspected pulmonary IFI [96]. The lateral-flow device (LFD) is another promising test. This point of care test detects *Aspergillus* glycoprotein antigen in both serum and BAL has been studied in adult cohorts [97,98]. While these novel diagnostics shows promise, they have not yet been evaluated in children.

3.2.6. Radiology

Plain film and computer tomography (CT) are used for the diagnosis of pulmonary IA, though radiographic findings overlap with those of other IFI. CT has higher sensitivity and specificity for early diagnosis of pulmonary IA [99,100]. Radiographic findings that are described as characteristic in adult pulmonary IA are less common in children. These include the ‘halo sign’ that occurs earlier in the course of infection, as well as cavitation and the ‘air crescent’ sign that occur upon immune reconstitution [10,101–103].

More commonly, pediatric patients with pulmonary IA have nodules, masses, peripheral infiltrates, consolidations, and pleural effusions [10,29,101,102,104]. In a retrospective review of pediatric patients with proven or probable pulmonary IA, the most common findings on CT or plain radiograph were nodules (59%) [10]. Nodules were more commonly reported in older compared to younger children (63% ≥13 year-olds vs. 72%, 6–12 year-olds vs. 39%, 0–5 year-olds). Cavities were reported in 25% of patients and a minority of patients had the halo (11%) and air crescent (2%) signs. The reasons for the lower rates of cavitation and the halo and air crescent signs in children are unknown but differences in pathophysiology, immune response, and timing of imaging are possible explanations [10,101–103].

Radiographic findings of sinus and CNS IA are nonspecific. Common radiographic findings of sinus IA are mucosal thickening (67%), opacification (48%), and air fluid levels (24%) [10]. Radiographic findings of CNS IA include hypoattenuating lesions on CT and T2 hyperintense lesions on MRI, single or multiple ring enhancing lesions, or dural enhancement abutting sinus disease [105,106].

4. Treatment

During the last 15 years, multiple new antifungals have become available for treatment of IA, expanding options within three different antifungal classes. However, licensing of new antifungals for use in children lags behind adult approvals, and there are important age-specific pharmacokinetic differences. Table 3 summarizes the antifungals with activity against *Aspergillus*, their current pediatric licensing status and evidence and/or consensus guidelines supporting their use in children with IA. Off-label use of medications is common in pediatrics and agents may be commonly used for age groups and/or indications that lack regulatory approval [6,10,107].
Table 3. Antifungals for Treatment of Invasive Aspergillosis: Pediatric Licensing and Evidence Supporting Use in Children.

| Class/Agent (Formulation—IV \(^a\)/PO \(^b\)) | Ages Currently Licensed \(^c\) | Pediatric Evidence | Clinical Guidelines |
|-----------------------------------------------|-------------------------------|--------------------|---------------------|
| Polyenes                                      |                               |                    |                     |
| Amphotericin B deoxycholate (IV)              | All                           | First available agent |                     |
| Liposomal amphotericin B (IV)                 | ≥1 month                       | PK \(^d\), safety [108]. Observational cohort study [109] | IDSA \(^d\): alternative primary therapy (A-I), salvage therapy (A-II). ECIL-4 \(^e\): 1st line (B-I), 2nd line (B-II) |
| Amphotericin B lipid complex (IV)             | All                           | Observational cohort study [110]. Non-comparative trial (salvage therapy) [111] | IDSA: alternative primary therapy (A-I), salvage therapy (A-II). ECIL-4: 1st line (B-II), 2nd line (B-II) |
| Amphotericin B colloidal dispersion (IV)      | All (no longer commercially available) | Non-comparative trial (salvage therapy) [112] | IDSA: alternative primary therapy (A-I), salvage therapy (A-II) |
| Triazoles                                     |                               |                    |                     |
| Voriconazole (IV, PO)                         | ≥12 years \(^f\)              | PK, safety [113–117]. Non-comparative trial (salvage therapy) [118]. RCT\(^f\) including children ≥12 years [119] | IDSA: primary therapy (A-I). ECIL-4: first line (A-I), second line for voriconazole-naïve patients (A-I) |
| Itraconazole (PO)                             | ≥18 years                     | PK, safety [120] | IDSA: salvage therapy (B-II). ECIL-4: 2nd line (no grade) |
| Posaconazole (IV, PO)                         | PO: ≥13 years. IV: ≥18 years  | PK, safety [121–124]. Retrospective cohort study [125] | IDSA: salvage therapy (B-II). ECIL-4: 2nd line (no grade) |
| Isavuconazole (IV, PO)                        | ≥18 years                     | PK, safety |                     |
| Echinocandins                                 |                               |                    |                     |
| Caspofungin (IV)                              | ≥3 months                     | PK, safety [126–129]. Retrospective cohort study [130]. Non-comparative trial (primary & salvage therapy) [131] | IDSA: salvage therapy (B-II). ECIL-4: 2nd line (A-II) |
| Micafungin (IV)                               | ≥4 months                     | PK, safety [132–135]. Non-comparative trial (salvage therapy) including pediatric patients [136] | IDSA: salvage therapy (B-II). ECIL-4: 2nd line (no grade) |
| Anidulafungin (IV)                            | ≥18 years                     | PK, safety [137] |                     |

\(^a\) IV; intravenous; \(^b\) PO; oral; \(^c\) Licensing status by United States Food and Drug Administration; not all drugs are licensed for primary therapy of invasive aspergillosis; voriconazole, isavuconazole, and amphotericin B deoxycholate are licensed for primary therapy; lipid amphotericin B formulations and caspofungin are licensed for salvage therapy in patients who are intolerant or unresponsive to other agents; posaconazole is licensed only for prophylaxis in the United States, but is licensed for salvage therapy by the European Medications Agency. Micafungin and anidulafungin are not licensed for IA but have in vitro activity similar to caspofungin; \(^d\) PK; pharmacokinetics; \(^e\) IDSA; Infectious Diseases Society of America; combined adult and pediatric guidelines, evidence levels based on adult data [138]; \(^f\) ECIL-4; Fourth European Conference on Infections in Leukemia; pediatric-specific guidelines [139]. \(^\dagger\) RCT; randomized controlled trial; \(^\ddagger\) Voriconazole is approved by the European Medications Agency for children age 2–11 years.
4.1. Amphotericin B Formulations (Polyenes)

Amphotericin B exerts fungicidal activity by binding to ergosterol and altering permeability of the fungal cell membrane. It is active against *Aspergillus* species except for *Aspergillus terreus* [140]. Conventional amphotericin B deoxycholate was the first available antifungal with activity against *Aspergillus*, and was for many years the only therapeutic option for IA. Its disadvantages are nephrotoxicity and infusion-related adverse effects. Lipid formulations of amphotericin B are better tolerated with less nephrotoxicity [111,112]. Though they differ from one another and from the parent drug in pharmacokinetics, there is no available evidence showing differences in efficacy between any of the formulations [141]. Differences in tissue distribution should be considered when treating infections at specific sites, such as the CNS, because tissue distribution varies between formulations [142]. Lipid amphotericin B formulations remain options for treatment of patients who are intolerant or unresponsive to voriconazole [138,139]. Their potential advantages include lack of drug interactions and broader spectrum of antifungal activity, for patients in whom IA is not confirmed and other fungi are suspected.

4.2. Triazoles

Triazoles inhibit biosynthesis of ergosterol in the fungal cell membrane, and are fungicidal against *Aspergillus* [143]. Itraconazole was the first available triazole with activity against *Aspergillus*, but its use for treatment of IA in children is limited due to unreliable bioavailability [120]. Voriconazole became the first line antifungal for IA based on a clinical trial demonstrating superior efficacy and tolerability of voriconazole compared to amphotericin B deoxycholate among patients 12 years and older with definite or probable IA [119,138]. Survival at 12 weeks of therapy was 70.8% in the voriconazole group compared to 57.9% in the amphotericin B group, and severe drug-related adverse events were less common with voriconazole [119]. Although there are no comparative trials in children with IA under 12 years, voriconazole is recommended as primary therapy for pediatric IA based on pediatric safety data and a non-comparative compassionate use study demonstrating complete or partial response to voriconazole in 45% of children with IA and other IFIs who were refractory to or intolerant of conventional therapy [118,139].

Substantially higher doses of voriconazole are needed in young children (<12 years) to achieve adequate drug exposure [113–117]. This is due to linear voriconazole elimination kinetics in children over a wider range of doses compared to adults and adolescents, who have non-linear elimination kinetics at usual doses [113]. Non-linear kinetics result in large increases in exposure with small dose increases, and can be observed in younger children receiving higher voriconazole doses. Additionally, the oral formulation of voriconazole has lower bioavailability in children (44%–65%) compared to adults (>90%); this may be due to more extensive intestinal first pass metabolism in children [114,115,144].

There is substantial inter-patient variability in voriconazole exposure, partly due to polymorphisms in CYP2C19, and this variability may be greater in children than in adults [113–116,145]. Therapeutic drug monitoring (TDM) of voriconazole is recommended with a target trough range of 1.0–5.0 mg/L [139]. Correlation of treatment failure with trough levels <1.0 mg/L has been shown in young children as well as adolescents and adults [146–149]. A recent meta-analysis showed clear associations between therapeutic voriconazole levels and treatment success, and between supra-therapeutic levels and toxicity [150]. Voriconazole TDM has demonstrated benefits in children and adults, by reducing avoidable discontinuation of voriconazole and increasing likelihood of a successful response to therapy [149,151].

The most common adverse events associated with voriconazole include hepatic abnormalities, visual changes, and rash, often attributable to photosensitization [113,115,116,118,119]. Less common but serious toxicities include neurotoxicity (confusion and/or hallucination) and prolongation of the QT interval with associated arrhythmias [116,119,152]. Children receiving voriconazole prophylaxis have developed severe phototoxic skin reactions; the mechanism of this reaction is unknown [153,154].
Long term voriconazole exposure has been associated with acceleration of chronic phototoxicity and increased risk for skin cancers in immunocompromised patients [155]. Long term use of voriconazole has also been associated with elevated serum fluoride levels, with associated skeletal fluorosis and painful osteitis [156,157]. Voriconazole is an inhibitor of CYP3A4, CYP2C19 and CYP2C9 and is therefore subject to multiple drug interactions.

Newer triazole agents, posaconazole and isavuconazole, may serve a greater role for therapy of pediatric IA in the future, but their use is currently limited by a paucity of pediatric data. Although there are no published clinical trials comparing efficacy of posaconazole against voriconazole for IA, it is recommended as an option for salvage therapy in patients >13 years of age on the basis of an externally controlled clinical trial in adults and adolescents with IA who were refractory to or intolerant of standard therapy [138,139,158]. It is available in oral suspension, oral tablet and IV formulations. Bioavailability of the oral suspension is unreliable and dependent on food intake [159]. This formulation has undergone limited evaluation in children, with observational studies characterizing pharmacokinetics, safety and efficacy in prophylaxis of invasive mycoses [122–124]. Preliminary results of a more extensive pediatric pharmacokinetic study indicate that target concentration attainment with the posaconazole oral suspension is poor, especially in young children [160]. The safety profile of posaconazole appears favorable, and further pharmacokinetic studies are in progress to establish optimal dosing of posaconazole in children, especially with the newer formulations, which are dosed differently than the suspension.

Isavuconazole, the most recently developed triazole, was found to be non-inferior to voriconazole for IA in adults [161]. Its potential advantages over voriconazole include broader spectrum of activity (including activity against mucormycosis), reliable pharmacokinetics, and a favorable safety profile [162]. However, there are currently no data to establish its use in children.

4.3. Echinocandins

Echinocandins inhibit synthesis of 1,3-β-D-glucan in the fungal cell wall and are fungistatic against Aspergillus. Caspofungin and micafungin are the best evaluated in children and have a favorable safety profile across multiple pediatric age groups [126,127,131–133]. Caspofungin and micafungin have been evaluated in non-comparative studies for treatment of patients with IA, including small numbers of children, mostly as salvage therapy for patients refractory to or intolerant of other agents [131,136]. Because of their fungistatic activity and lack of robust data for use as primary therapy, the echinocandins are recommended as second line therapy for IA in patients who are intolerant to or refractory to first line agents [138,139].

4.4. Combination Antifungal Therapy

Though not routinely recommended for primary IA therapy, use of combination antifungal therapy is common in both children and adults. Two recent multicenter pediatric cohort studies reported use of combination therapy in 46% and 54% of children with IA [6,10]. In one of these studies, children who received combination therapy were more likely to experience adverse events compared to those treated with monotherapy [6]. A recent clinical trial comparing voriconazole monotherapy to voriconazole and anidulafungin combination therapy for primary therapy of adults with IA showed a trend toward lower mortality with combination therapy (19.3% vs. 27.5% at 6 weeks; p = 0.087) but was underpowered for this primary endpoint [163]. The implications for management of children with IA are uncertain; recent European guidelines propose combination therapy as an option for pediatric IA, but with weak recommendations [139]. Combination therapy deserves further evaluation for safety and efficacy in children, given the major differences in antifungal pharmacology in children and adults.

4.5. Adjunctive Therapies

Colony stimulating factors and other therapies intended to reverse predisposing conditions and augment the immune response to Aspergillus are commonly given to children with IA [6,10,22].
As in adults, their specific contribution to clinical outcomes is uncertain, but an effect is biologically plausible due to the importance of immune reconstitution in recovery from IA. Adoptive transfer of donor-derived pathogen-specific T cells, a strategy used successfully against viral infections in HSCT recipients, is a promising option for IA therapy and is currently in early clinical development [164,165]. Many children with IA undergo surgery for disease control, with indications similar to those in adults; one pediatric study identified an association between surgical treatment and improved survival [10,22].

5. Conclusions

Important differences in diagnosis and treatment exist between adult and pediatric IA. Although there have been advances in the diagnosis, treatment, and outcomes of pediatric IA, challenges remain. Better characterization of IA in pediatric populations, such as those with SOT and primary immunodeficiencies, is needed. The greatest gains are likely to come from optimizing the diagnostic approach to IA, including incorporation of risk stratification, and establishing algorithms to determine which patients may be best evaluated through non-invasive tests, versus those that could benefit from invasive testing. Additional evaluation of combination antifungal therapy and pediatric studies of new antifungals will facilitate broader prophylaxis and treatment options in at-risk children. Novel treatment strategies such as immunotherapy may also play a role in the treatment of pediatric IA. Taken together, improved diagnostic and treatment modalities will enable earlier diagnosis and improve mortality for children with IA.

Acknowledgments: Rachel L. Wattier is supported by an Early Career Award from the Thrasher Research Foundation (TRF11939). Lynn Ramirez-Avila is supported through the UCSF John A. Watson Faculty Scholars Program.

Author Contributions: Rachel L. Wattier prepared the “Epidemiology” and “Treatment” sections. Lynn Ramirez-Avila prepared the “Clinical Presentation and Diagnosis” section. Authors revised the entire manuscript jointly.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. McNeil, M.M.; Nash, S.L.; Hajjeh, R.A.; Phelan, M.A.; Conn, L.A.; Plikaytis, B.D.; Warnock, D.W. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin. Infect. Dis. 2001, 33, 641–647. [CrossRef] [PubMed]
2. Rosen, G.P.; Nielsen, K.; Glenn, S.; Abelson, J.; Deville, J.; Moore, T.B. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J. Pediatr. Hematol. Oncol. 2005, 27, 135–140. [CrossRef] [PubMed]
3. Rubio, P.M.; Sevilla, J.; González-Vicent, M.; Lassaletta, A.; Cuenda-Estrada, M.; Díaz, M.A.; Riesco, S.; Madero, L. Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: A retrospective single centre study. J. Pediatr. Hematol. Oncol. 2009, 31, 642–646. [CrossRef] [PubMed]
4. Pappas, P.G.; Alexander, B.D.; Andes, D.R.; Hadley, S.; Kauffman, C.A.; Freifeld, A.; Anaissie, E.J.; Brumble, L.M.; Herwaldt, L.; Ito, J.; et al. Invasive fungal infections among organ transplant recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 2010, 50, 1101–1111. [CrossRef] [PubMed]
5. Jain, S.; Kapoor, G. Invasive aspergillosis in children with acute leukemia at a resource-limited oncology center. J. Pediatr. Hematol. Oncol. 2015, 37, e1–e5. [CrossRef] [PubMed]
6. Wattier, R.L.; Dvorak, C.C.; Hoffman, J.A.; Brozovich, A.A.; Bin-Hussain, I.; Groll, A.H.; Castagnola, E.; Knapp, K.M.; Zauutis, T.E.; Gustafsson, B.; et al. A prospective, international cohort study of invasive mold infections in children. J. Pediatric Infect. Dis. Soc. 2015, 4, 313–322. [CrossRef] [PubMed]
7. Domenech, C.; Leick-Courtois, C.; Picot, S.; Bleyzac, N. Improvement in the outcome of invasive aspergillosis in a pediatric hematology department: A 10-Year review. J Pediatr Hematol Oncol 2015, 37, 560–565. [CrossRef] [PubMed]
8. Zaoutis, T.E.; Heydon, K.; Chu, J.H.; Walsh, T.J.; Steinbach, W.J. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. *Pediatrics* **2006**, *117*, e711–e716. [CrossRef] [PubMed]

9. Shetty, D.; Giri, N.; Gonzalez, C.E.; Pizzo, P.A.; Walsh, T.J. Invasive aspergillosis in human immunodeficiency virus-infected children. *Pediatr. Infect. Dis. J.* **1997**, *16*, 216–221. [CrossRef] [PubMed]

10. Burgos, A.; Zaoutis, T.E.; Dvorak, C.C.; Hoffman, J.A.; Knapp, K.M.; Nania, J.J.; Prasad, P.; Steinbach, W.J. Pediatric invasive aspergillosis: A multicenter retrospective analysis of 139331 cases. *Pediatrics* **2008**, *121*, e1286–e1294. [CrossRef] [PubMed]

11. Al-Rezqi, A.; Hawkes, M.; Doyle, J.; Richardson, S.E.; Allen, U. Invasive mold infections in iatrogenically immunocompromised children: An eight-yr review. *Pediatr. Transplant.* **2009**, *13*, 545–552. [CrossRef] [PubMed]

12. Silva, M.F.; Ribeiro, A.S.; Fiorot, F.J.; Aikawa, N.E.; Lotito, A.P.; Campos, L.M.; Mauad, T.; Silva, C.A. Invasive aspergillosis: A severe infection in juvenile systemic lupus erythematosus patients. *Lupus* **2012**, *21*, 1011–1016. [CrossRef] [PubMed]

13. Papouli, M.; Rolides, E.; Bibashi, E.; Andreou, A. Primary cutaneous aspergillosis in neonates: Case report and review. *Clin. Infect. Dis.* **1996**, *22*, 1102–1104. [CrossRef] [PubMed]

14. Abbasi, S.; Shene, J.L.; Hughes, W.T.; Flynn, P.M. Aspergillosis in children with cancer: A 34-year experience. *Clin. Infect. Dis.* **1999**, *29*, 1210–1219. [CrossRef] [PubMed]

15. Ducassou, S.; Rivaud, D.; Auvrignon, A.; Verite, C.; Bertrand, Y.; Gandemer, V.; Leverger, G. Invasive fungal infections in pediatric acute myelogenous leukemia. *Pediatr. Infect. Dis. J.* **2015**, *34*, 1262–1264. [CrossRef] [PubMed]

16. Benjamin, D.K., Jr.; Miller, W.C.; Bayliff, S.; Martel, L.; Alexander, K.A.; Martin, P.L. Infections diagnosed in the first year after pediatric stem cell transplantation. *Pediatr. Infect. Dis. J.* **2002**, *21*, 227–234. [CrossRef] [PubMed]

17. Marciano, B.E.; Spalding, C.; Fitzgerald, A.; Mann, D.; Brown, T.; Osgood, S.; Yockey, L.; Darnell, D.N.; Barnhart, L.; Daub, J.; et al. Common severe infections in chronic granulomatous disease. *Clin. Infect. Dis.* **2014**, *60*, 1176–1183. [CrossRef] [PubMed]

18. Vinh, D.C.; Sugui, J.A.; Hsu, A.P.; Freeman, A.F.; Holland, S.M. Invasive fungal disease in autosomal-dominant hyper-IgE syndrome. *J. Allergy Clin. Immunol.* **2010**, *125*, 1389–1390. [CrossRef] [PubMed]

19. Antachopoulos, C. Invasive fungal infections in congenital immunodeficiencies. *Clin. Microbiol. Infect.* **2010**, *16*, 1335–1342. [CrossRef] [PubMed]

20. Steinbach, W.J.; Marr, K.A.; Anaissie, E.J.; Azie, N.; Quan, S.P.; Meier-Kriesche, H.U.; Apewokin, S.; Horn, D.L. Clinical epidemiology of 97076 with invasive aspergillosis from the PATH Alliance registry. *J. Infect.* **2012**, *65*, 453–464. [CrossRef] [PubMed]

21. Walsmsley, S.; Devi, S.; King, S.; Schneider, R.; Richardson, S.; FordJones, L. Invasive Aspergillus infections in a pediatric hospital - a 10-year review. *Pediatr. Infect. Dis. J.* **1993**, *12*, 673–682. [CrossRef] [PubMed]

22. Georgiadou, S.P.; Pongas, G.; Fitzgerald, N.E.; Lewis, R.E.; Ryting, M.; Marom, E.M.; Kontoyiannis, D.P. Invasive mold infections in pediatric cancer patients reflect heterogeneity in etiology, presentation, and outcome: A 10-year, single-institution, retrospective study. *J. Pediatr. Infect. Dis. Soc.* **2012**, *1*, 125–135. [CrossRef] [PubMed]

23. Bernardeschi, C.; Foulet, F.; Ingen-Housz-Oro, S.; Ortonne, N.; Sitbon, K.; Quereux, G.; Lortholary, O.; Chosidow, O.; Bretagne, S. Cutaneous invasive aspergillosis: Retrospective multicenter study of the French Invasive-Aspergillosis Registry and literature review. *Medicine* **2015**, *94*, e1018. [CrossRef] [PubMed]

24. Lin, S.; Schranz, J.; Teutsch, S.M. Aspergillosis case-fatality rate: Systematic review of the literature. *Clin. Infect. Dis.* **2001**, *32*, 358–366. [CrossRef] [PubMed]

25. Han, S.B.; Kim, S.; Bae, E.Y.; Lee, J.W.; Yoon, J.-S.; Chung, N.-G.; Cho, B.; Jeong, D.C.; Kang, J.H.; Kim, H.-K.; Lee, D.; Lee, H.S. Clinical features and prognosis of invasive pulmonary aspergillosis in Korean children with hematologic/oncologic diseases. *J. Korean Med. Sci.* **2015**, *30*, 1121–1128. [CrossRef] [PubMed]

26. Crassard, N.; Hadden, H.; Piens, M.A.; Pondarrè, C.; Hadden, R.; Galambrun, C.; Pracros, J.P.; Souillet, G.; Basset, T.; Berthier, J.C.; Philippe, N.; Bertrand, Y. Invasive aspergillosis in a paediatric haematology department: A 15-year review. *Mycoses* **2008**, *51*, 109–116. [CrossRef] [PubMed]
27. Cakır, F.B.; Cakır, E.; Berrak, S.G.; Uyan, Z.S.; Canpolat, C.; Karakoc, F.; Dagli, E. Invasive respiratory aspergillosis is a treatable disease with early diagnosis and aggressive therapy. Pediatr. Hematol. Oncol. 2010, 27, 422–434. [CrossRef] [PubMed]

28. Groll, A.H.; Kurz, M.; Schneider, W.; Witt, V.; Schmidt, H.; Schneider, M.; Schwabe, D. Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival. Mycoses 1999, 42, 431–442. [CrossRef] [PubMed]

29. Wright, J.A.; Bradfield, S.M.; Park, J.R.; Hawkins, D.S. Prolonged survival after invasive aspergillosis: A single-institution review of 11 cases. J. Pediatr. Hematol. Oncol. 2003, 25, 286–291. [CrossRef] [PubMed]

30. Antachopoulos, C.; Walsh, T.J.; Roilides, E. Fungal infections in primary immunodeficiencies. Eur. J. Pediatr. 2007, 166, 1099–1117. [CrossRef] [PubMed]

31. Choi, S.-H.; Kang, E.-S.; Eo, H.; Yoo, S.-Y.; Kim, J.H.; Yoo, K.H.; Sung, K.W.; Koo, H.H.; Kim, Y.-J. Aspergillus galactomannan antigen assay and invasive aspergillosis in pediatric cancer patients and hematopoietic stem cell transplant recipients. Pediatr. Blood Cancer 2013, 60, 316–322. [CrossRef] [PubMed]

32. Woodruff, C.A.; Hebert, A.A. Neonatal primary cutaneous aspergillosis: Case report and review of the literature. Pediatr. Dermatol. 2002, 19, 439–444. [CrossRef] [PubMed]

33. Rogdo, B.; Kahler, C.; Diener, P.A.; Micallef, J. Primary cutaneous aspergillosis in a preterm neonate. BMJ Case Rep. 2014, 2014. [CrossRef] [PubMed]

34. Simpson, C.L.; Boos, M.D.; Castelo-Soccio, L. A crusted papule in a premature neonate. Cutaneous fungal infection. JAMA Pediatr. 2015, 169, 1173–1174. [CrossRef] [PubMed]

35. Broenen, E.; Mavinkurve-Groothuis, A.; Kamphuis-van Ulzen, K.; Brüggemann, R.; Verweij, P.; Warris, A. Screening of the central nervous system in children with invasive pulmonary aspergillosis. Med. Mycol. Case Rep. 2014, 4, 8–11. [CrossRef] [PubMed]

36. Badawy, S.M.; Becktell, K.D.; Muller, W.J.; Schneiderman, J. Aspergillus thyroiditis: First antemortem case diagnosed by fine-needle aspiration culture in a pediatric stem cell transplant patient. Transpl. Infect. Dis. 2015, 17, 868–871. [CrossRef] [PubMed]

37. Kalokhe, A.S.; Rouphael, N.; El Chami, M.F.; Workowski, K.A.; Ganesh, G.; Jacob, J.T. Aspergillus endocarditis: A review of the literature. Int. J. Infect. Dis. 2010, 14, e1040–e1047. [CrossRef] [PubMed]

38. Gamaletou, M.N.; Rammaert, B.; Bueno, M.A.; Moriyama, B.; Sipsas, N.V.; Kontoyiannis, D.P.; Roilides, E.; Zeller, V.; Prinapori, R.; Taj-Aldeen, S.J.; et al. Aspergillus oesteomyelitis: Epidemiology, clinical manifestations, management, and outcome. J. Infect. 2014, 68, 478–493. [PubMed]

39. Green, K.K.; Barham, H.P.; Allen, G.C.; Chan, K.H. Prognostic factors in the outcome of invasive fungal sinusitis in a pediatric population. Pediatr. Infect. Dis. J. 2016, 35, 384–386. [CrossRef] [PubMed]

40. Mor, M.; Gilad, G.; Kornreich, L.; Fisher, S.; Yaniv, I.; Levy, I. Invasive fungal infections in pediatric oncology. Pediatr. Blood Cancer 2011, 56, 1092–1097. [CrossRef] [PubMed]

41. Ascioglu, S.; Rex, J.H.; de Pauw, B.; Bennett, J.E.; Bille, J.E.; Bille, J.; Crokaert, F.; Denning, D.W.; Donnelly, J.P.; Edwards, J.E.; et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin. Infect. Dis. 2002, 34, 7–14. [CrossRef] [PubMed]

42. De Pauw, B.; Walsh, T.J.; Donnelly, J.P.; Stevens, D.A.; Edwards, J.E.; Calandra, T.; Pappas, P.G.; Maertens, J.; Lortholary, O.; Kauffman, C.A.; et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) C. Clin. Infect. Dis. 2008, 46, 1813–1821. [CrossRef] [PubMed]

43. Qualter, E.; Satwani, P.; Ricci, A.; Jin, Z.; Geyer, M.B.; Aloibeid, B.; Radhakrishnan, K.; Bye, M.; Middlesworth, W.; Della-Letta, P.; et al. A comparison of bronchoalveolar lavage versus lung biopsy in pediatric recipients after stem cell transplantation. Biol. Blood Marrow Transplant. 2014, 20, 1229–1237. [CrossRef] [PubMed]

44. Verweij, P.E.; Chowdhary, A.; Melchers, W.J.G.; Meis, J.F. Azole resistance in Aspergillus fumigatus: Can we retain the clinical use of mold-active antifungal azoles? Clin. Infect. Dis. 2016, 62, 362–368. [CrossRef] [PubMed]

45. Steinbach, W.J.; Addison, R.M.; McLaughlin, L.; Gerrald, Q.; Martin, P.L.; Driscoll, T.; Bentsen, C.; Perfect, J.R.; Alexander, B.D. Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr. Infect. Dis. J. 2007, 26, 558–564. [CrossRef] [PubMed]
46. Badiee, P.; Alborzi, A.; Karimi, M.; Pourrabas, B.; Haddadi, P.; Mardaneh, J.; Moieni, M. Diagnostic potential of nested PCR, galactomannan ELA, and beta-D-glucan for invasive aspergillosis in pediatric patients. J. Infect. Dev. Ctries. 2012, 6, 352–357. [CrossRef] [PubMed]

47. Fisher, B.T.; Zaoutis, T.E.; Park, J.R.; Bleakley, M.; Englund, J.A.; Kane, C.; Arceci, R.J.; Guinan, E.; Smith, F.O.; Luan, X.; et al. Galactomannan antigen testing for diagnosis of invasive aspergillosis in pediatric hematologic patients. J. Pediatric Infect. Dis. Soc. 2012, 1, 103–111. [CrossRef] [PubMed]

48. Hayden, R.; Pounds, S.; Knapp, K.; Petraitiiene, R.; Schaufele, R.L.; Sein, T.; Walsh, T.J. Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis. Pediatr. Infect. Dis. J. 2008, 27, 815–819. [CrossRef] [PubMed]

49. Jha, A.K.; Bansal, D.; Chakrabarti, A.; Shivaprakash, M.R.; Trehan, A.; Marwaha, R.K. Serum galactomannan assay for the diagnosis of invasive aspergillosis in children with haematological malignancies. Mycoses 2013, 56, 442–448. [CrossRef] [PubMed]

50. Gefen, A.; Zaidman, I.; Shachor-Meyouhas, Y.; Avidor, I.; Hakim, F.; Weyl Ben-Arush, M.; Kassis, I. Serum galactomannan screening for diagnosis of invasive pulmonary aspergillosis in children after stem cell transplantation or with high-risk leukemia. Pediatr. Hematol. Oncol. 2015, 32, 146–152. [CrossRef] [PubMed]

51. Dinand, V.; Anjan, M.; Oberoi, J.K.; Khanna, S.; Yadav, S.P.; Wattal, C.; Sachdeva, A. Threshold of galactomannan antigenemia positivity for early diagnosis of invasive aspergillosis in neutropenic children. J. Microbiol. Immunol. Infect. 2016, 49, 66–73. [CrossRef] [PubMed]

52. Pfeiffer, C.D.; Fine, J.P.; Safdar, N. Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clin. Infect. Dis. 2006, 42, 1417–1427. [CrossRef] [PubMed]

53. Leefflang, M.M.; Debits-Ossenkopp, Y.J.; Visser, C.E.; Scholten, R.J.; Hoof, L.; Bijlmer, H.A.; Reitsma, J.B.; Bossuyt, P.M.; Vandenbroucke-Grauls, C.M. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst. Rev. 2008, 8, CD007394. [PubMed]

54. Leefflang, M.M.; Debits-Ossenkopp, Y.J.; Wang, J.; Visser, C.E.; Scholten, R.J.; Hoof, L.; Bijlmer, H.A.; Reitsma, J.B.; Zhang, M.; Bossuyt, P.M.; et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst. Rev. 2015, 12, CD007394. [PubMed]

55. Arvanitis, M.; Anagnostou, T.; Mylonakis, E. Galactomannan and polymerase chain reaction-based screening for invasive aspergillosis in pediatric patients with cancer and hematologic disorders. Pediatr. Blood Cancer 2007, 48, 28–34. [CrossRef] [PubMed]

56. Siemann, M.; Koch-Dörfler, M.; Gaude, M. False-positive results in premature infants with the Platelia Aspergillus sandwich enzyme-linked immunosorbent assay. Mycoses 1998, 41, 373–377. [CrossRef] [PubMed]

57. Herbrecht, R.; Letscher-Bru, V.; Oprea, C.; Liouere, B.; Waller, J.; Campos, F.; Villard, O.; Liu, K.L.; Natarajan-Amé, S.; Lutz, P.; et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J. Clin. Oncol. 2002, 20, 1898–1906. [CrossRef] [PubMed]

58. Kornmann, C.; Dörfler, M.; Guade, M. False-positive results in immature infants with the Platelia Aspergillus sandwich enzyme-linked immunosorbent assay. Mycoses 1998, 41, 373–377. [CrossRef] [PubMed]

59. Mennink-Kersten, M.A.; Ruegebrink, D.; Klont, R.R.; Warris, A.; Gavini, F.; Op den Camp, H.J.; Verweij, P.E. Bifidobacterial lipoglycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity. J. Microbiol. Immunol. Infect. 2005, 43, 3925–3931. [CrossRef] [PubMed]

60. Herbrecht, R.; Letscher-Bru, V.; Oprea, C.; Liouere, B.; Waller, J.; Campos, F.; Villard, O.; Liu, K.L.; Natarajan-Amé, S.; Lutz, P.; et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J. Clin. Oncol. 2002, 20, 1898–1906. [CrossRef] [PubMed]

61. Dornbusch, H.J.; Groll, A.; Walsh, T.J. Diagnosis of invasive fungal infections in immunocompromised children. Clin. Microbiol. Infect. 2010, 16, 1328–1334. [CrossRef] [PubMed]

62. Lamoth, F.; Cruciani, M.; Mengoli, C.; Castagnola, E.; Lortholary, O.; Richardson, M.; Marchetti, O. β-glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: A systematic review and meta-analysis of cohort studies from the third European Conference on Infections in Leukemia (ECIL-3). Clin. Infect. Dis. 2012, 54, 633–643. [CrossRef] [PubMed]

63. Fisher, B.T. The role of biomarkers for diagnosis of and therapeutic decisions related to invasive aspergillosis in children. Curr. Fungal Infect. Rep. 2013, 7, 7–14. [CrossRef] [PubMed]
64. Nucci, M.; Carlesse, F.; Cappellano, P.; Varon, A.G.; Seber, A.; Garnica, M.; Nouéř, S.A.; Colombo, A.L. Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing. PLoS ONE 2014, 9, e87784. [CrossRef] [PubMed]

65. Marty, F.M.; Koo, S. Role of (1->3)-β-D-glucan in the diagnosis of invasive aspergillosis. Med. Mycol. 2009, 47 (Suppl. 1), S233–S240. [CrossRef] [PubMed]

66. Prattes, J.; Schilcher, G.; Krause, R. Reliability of serum 1,3-β-D-glucan assay in patients undergoing renal replacement therapy: A review of the literature. Mycoses 2015, 58, 4–9. [CrossRef] [PubMed]

67. Goudjil, S.; Kongolo, G.; Dusol, L.; Imestouren, F.; Cornu, M.; Leke, A.; Chouaki, T. (1-3)-β-D-glucan levels in candidiasis infections in the critically ill neonate. J. Matern. Fetal. Neonatal Med. 2013, 26, 44–48. [CrossRef] [PubMed]

68. D’Haese, J.; Theunissen, K.; Vermeulen, E.; Schoemans, H.; De Vlieger, G.; Lammertijn, L.; Meersseman, P.; Meersseman, W.; Lagrou, K.; Maertens, J. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: Analytical and clinical validity. J. Clin. Microbiol. 2012, 50, 1258–1263. [CrossRef] [PubMed]

69. Desai, R.; Ross, L.A.; Hoffman, J.A. The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis. Pediatr. Infect. Dis. J. 2009, 28, 283–286. [CrossRef] [PubMed]

70. Marr, K.A.; Balajee, S.A.; McLaughlin, L.; Taboure, M.; Bentzen, C.; Walsh, T.J. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance. J. Infect. Dis. 2009, 190, 641–649. [CrossRef] [PubMed]

71. Blumental, S.; Mouy, R.; Mahlaoui, N.; Bougnoux, M.E.; Debré, M.; Beauté, J.; Lortholary, O.; Blanche, S.; Fischer, A. Invasive mold infections in chronic granulomatous disease: A 25-year retrospective survey. Clin. Infect. Dis. 2011, 53, e159–e169. [CrossRef] [PubMed]

72. Han, S.B.; Kim, S.K.; Lee, J.W.; Yoon, J-S.; Chung, N.-G.; Cho, B.; Jeong, D.C.; Kang, J.H.; Kim, H.-K.; Lee, D.-G.; et al. Serum galactomannan index for early prediction of mortality in immunocompromised children with invasive pulmonary aspergillosis. BMC Infect. Dis. 2015, 15, 271. [CrossRef] [PubMed]

73. Nucci, M.; Carlesse, F.; Cappellano, P.; Varon, A.G.; Seber, A.; Garnica, M.; Nouéř, S.A.; Colombo, A.L. Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing. PLoS ONE 2014, 9, e87784. [CrossRef] [PubMed]

74. Miceli, M.H.; Grazziutti, M.L.; Woods, G.; Zhao, W.; Kocoglu, M.H.; Barlogie, B.; Anaissie, E. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: Clinical and research implications. Clin. Infect. Dis. 2008, 46, 1412–1422. [CrossRef] [PubMed]

75. Bergeron, A.; Porcher, R.; Menotti, J.; Poiriot, J-L.; Chagnon, K.; Vekhoff, A.; Cornet, M.; Issard, F.; Raffoux, E.; Brethom, B.; et al. Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients. J. Clin. Microbiol. 2012, 50, 823–830. [CrossRef] [PubMed]

76. De Mol, M.; de Jongste, J.C.; van Westreenen, M.; Merkus, P.J.; de Vries, A.H.; Hop, W.C.; Warris, A.; Janssens, H.M. Diagnosis of invasive pulmonary aspergillosis in children with bronchoalveolar lavage galactomannan. Pediatr. Pulmonol. 2013, 48, 789–796. [CrossRef] [PubMed]

77. Chong, G.M.; Maertens, J.A.; Lagrou, K.; Driessen, G.J.; Cornelissen, J.J.; Rijnders, B.J. Diagnostic performance of galactomannan antigen testing in cerebrospinal fluid. J. Clin. Microbiol. 2016, 54, 428–431. [CrossRef] [PubMed]

78. Odabasi, Z.; Mattiuuzzi, G.; Estey, E.; Kantarjian, H.; Saeki, F.; Ridge, R.J.; Ketchum, P.A.; Finkelman, M.A.; Rex, J.H.; Ostrosky-Zeichner, L. β-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin. Infect. Dis. 2004, 39, 199–205. [CrossRef] [PubMed]

79. Sulahian, A.; Porcher, R.; Bergeron, A.; Touratier, S.; Raffoux, E.; Menotti, J.; Derouin, F.; Ribaud, P. Use and limits of (1-3)-β-D-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis. J. Clin. Microbiol. 2014, 52, 2328–2333. [CrossRef] [PubMed]

80. Mularoni, A.; Furfaro, E.; Faraci, M.; Franceschi, A.; Mezzano, P.; Bandettini, R.; Viscoli, C.; Castagnola, E. High levels of β-D-Glucan in immunocompromised children with proven invasive fungal disease. Clin. Vaccine Immunol. 2010, 17, 882–883. [CrossRef] [PubMed]
81. Koltze, A.; Rath, P.; Schöning, S.; Steinmann, J.; Wichelhaus, T.A.; Bader, P.; Bochennek, K.; Lehrnbecher, T. Beta-D-glucan screening for the detection of invasive fungal disease in children undergoing allogeneic hematopoietic stem cell transplantation. *J. Clin. Microbiol.* 2015, 53, 2605–2610. [CrossRef] [PubMed]

82. Salvatore, C.M.; Chen, T.K.; Toussi, S.S.; DeLaMora, P.; Petraitene, R.; Finkelman, M.A.; Walsh, T.J. (1→3)-β-D-glucan in cerebrospinal fluid as a biomarker for *Candida* and *Aspergillus* infections of the central nervous system in pediatric patients. *J. Pediatr. Infect. Dis. Soc.* 2015. [CrossRef] [PubMed]

83. Smith, P.B.; Benjamin, D.K., Jr.; Alexander, B.D.; Johnson, M.D.; Finkelman, M.A.; Steinbach, W.J. Quantification of 1,3-beta-D-glucan levels in children: Preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. *Clin. Vaccine Immunol.* 2007, 14, 924–925. [CrossRef] [PubMed]

84. Mokaddas, E.; Burhamah, M.H.; Khan, Z.U.; Ahmad, S. Levels of (1→3)-β-D-glucan, *Candida* mannann and *Candida* DNA in serum samples of pediatric cancer patients colonized with *Candida* species. *BMC Infect. Dis.* 2010, 10, 292. [CrossRef] [PubMed]

85. White, P.L.; Wingard, J.R.; Bretagne, S.; Löfler, J.; Patterson, T.F.; Slavin, M.A.; Barnes, R.A.; Pappas, P.G.; Donnelly, J.P. *Aspergillus* polymerase chain reaction: Systematic review of evidence for clinical use in comparison with antigen testing. *Clin. Infect. Dis.* 2015, 61, 1293–1303. [CrossRef] [PubMed]

86. Armenian, S.H.; Nash, K.A.; Kapoor, N.; Franklin, J.L.; Gaynon, P.S.; Ross, L.A.; Hoffman, J.A. Prospective monitoring for invasive aspergillosis using galactomannan and polymerase chain reaction in high risk pediatric patients. *J. Pediatr. Hematol. Oncol.* 2009, 31, 920–926. [CrossRef] [PubMed]

87. Buchheidt, D.; Reinwald, M.; Spiess, B.; Boch, T.; Hofmann, W.-K.; Groll, A.H.; Lehrnbecher, T. Biomarker-based diagnostic work-up of invasive pulmonary aspergillosis in immunocompromised paediatric patients - is *Aspergillus* PCR appropriate? *Mycoses* 2016, 59, 67–74. [CrossRef] [PubMed]

88. Hummel, M.; Spiess, B.; Roder, J.; von Komorowski, G.; Dürken, M.; Kentouche, K.; Laws, H.J.; Mörz, H.; Hehlmann, R.; Buchheidt, D. Detection of *Aspergillus* DNA by a nested PCR assay is able to improve the diagnosis of invasive aspergillosis in paediatric patients. *J. Med. Microbiol.* 2009, 58, 1291–1297. [CrossRef] [PubMed]

89. Reinwald, M.; Konietzka, C.A.; Kolve, H.; Uhlenbrock, S.; Ahlke, E.; Hummel, M.; Spiess, B.; Hofmann, W.-K.; Buchheidt, D.; Groll, A.H. Assessment of *Aspergillus*-specific PCR as a screening method for invasive aspergillosis in paediatric cancer patients and allogeneic haematopoietic stem cell recipients with suspected infections. *Mycoses* 2014, 57, 537–543. [CrossRef] [PubMed]

90. Cesaro, S.; Stenghele, C.; Calore, E.; Franchin, E.; Cerbaro, I.; Cusinato, R.; Tridello, G.; Manganelli, R.; Carli, M.; Palu, G. Assessment of the lightcycler PCR assay for diagnosis of invasive aspergillosis in paediatric patients with onco-haematological diseases. *Mycoses* 2008, 51, 497–504. [CrossRef] [PubMed]

91. White, P.L.; Posso, R.B.; Barnes, R.A. Analytical and clinical evaluation of the PathoNostics AsperGenius assay for detection of invasive aspergillosis and resistance to azole antifungal drugs during testing of serum samples. *J. Clin. Microbiol.* 2015, 53, 2115–2121. [CrossRef] [PubMed]

92. Chong, G.-L.; van de Sande, W.W.; Dingemans, G.J.; Gaajetaan, G.R.; Vonk, A.G.; Hayette, M.-P.; van Tegelen, D.W.; Simons, G.F.; Rijnders, B.J. Validation of a new *Aspergillus* real-time PCR assay for direct detection of *Aspergillus* and azole resistance of *Aspergillus fumigatus* on bronchoalveolar lavage fluid. *J. Clin. Microbiol.* 2015, 53, 868–874. [CrossRef] [PubMed]

93. Reinwald, M.; Buchheidt, D.; Hummel, M.; Duerken, M.; Bertz, H.; Schwerdtfeger, R.; Reuter, S.; Kiehl, M.G.; Barreto-Miranda, M.; Hofmann, W.K.; Spiess, B. Diagnostic performance of an *Aspergillus*-specific nested PCR assay in cerebrospinal fluid samples of immunocompromised patients for detection of central nervous system aspergillosis. *PLoS ONE* 2013, 8, e56706. [CrossRef] [PubMed]

94. Reinwald, M.; Spiess, B.; Heinz, W.J.; Heussel, C.P.; Bertz, H.; Cornely, O.A.; Hahn, J.; Lehrnbecher, T.; Kiehl, M.; Laws, H.J.; et al. *Aspergillus* PCR-based investigation of fresh tissue and effusion samples in patients with suspected invasive aspergillosis enhances diagnostic capabilities. *J. Clin. Microbiol.* 2013, 51, 4178–85. [CrossRef] [PubMed]

95. Babouee Flury, B.; Weisser, M.; Prince, S.S.; Bubendorf, L.; Battegay, M.; Frei, R.; Goldenberger, D. Performances of two different panfungal PCRs to detect mould DNA in formalin-fixed paraffin-embedded tissue: What are the limiting factors? *BMC Infect. Dis.* 2014, 14, 692. [CrossRef] [PubMed]

96. Koo, S.; Thomas, H.R.; Daniels, S.D.; Lynch, R.C.; Fortier, S.M.; Shea, M.M.; Rearden, P.; Comolli, J.C.; Baden, L.R.; Marty, F.M. A breath fungal secondary metabolite signature to diagnose invasive aspergillosis. *Clin. Infect. Dis.* 2014, 59, 1733–1740. [CrossRef] [PubMed]
97. Held, J.; Schmidt, T.; Thornton, C.R.; Kotter, E.; Bertz, H. Comparison of a novel Aspergillus lateral-flow device and the Platelia® galactomannan assay for the diagnosis of invasive aspergillosis following haematopoietic stem cell transplantation. *Infection 2013*, *41*, 1163–1169. [CrossRef] [PubMed]

98. Miceli, M.H.; Goggins, M.I.; Chandler, P.; Sekaran, A.K.; Kizy, A.E.; Samuel, L.; Jiang, H.; Thornton, C.R.; Ramesh, M.; Alangaden, G. Performance of lateral flow device and galactomannan for the detection of *Aspergillus* species in bronchoalveolar fluid of patients at risk for invasive pulmonary aspergillosis. *Mycoses 2015*, *58*, 368–374. [CrossRef] [PubMed]

99. Caillot, D.; Casasnovas, O.; Bernard, A.; Couaillier, J.F.; Durand, C.; Cuisenier, B.; Solary, E.; Piard, F.; Petrella, T.; Bonnin, A.; et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. *J. Clin. Oncol.* 1997, *15*, 139–147. [PubMed]

100. Hauggaard, A.; Ellis, M.; Ekelund, L. Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis. *Acta Radiol.* 2002, *43*, 292–298. [CrossRef] [PubMed]

101. Taccone, A.; Occhi, M.; Garaventa, A.; Manfredini, L.; Viscoli, C. CT of invasive pulmonary aspergillosis in children with cancer. *Pediatr. Radiol.* 1993, *23*, 177–180. [CrossRef] [PubMed]

102. Thomas, K.E.; Owens, C.M.; Veys, P.A.; Novelli, V.; Costoli, V. The radiological spectrum of invasive aspergillosis in children: A 10-year review. *Pediatr. Radiol.* 2003, *33*, 453–460. [PubMed]

103. Georgiadou, S.P.; Sipsas, N.V.; Marom, E.M.; Kontoyiannis, D.P. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. *Clin. Infect. Dis.* 2011, *52*, 1144–1155. [CrossRef] [PubMed]

104. Ankrah, A.O.; Sathekge, M.M.; Dierckx, R.A.; Glaudemans, A.W. Imaging fungal infections in children. *Radiographics 2016*, *36*, 577–590. [CrossRef] [PubMed]

105. Vázquez, E.; Lucaya, J.; Castellote, A.; Piquerás, J.; Sainz, P.; Olivé, T.; Sánchez-Toledo, J.; Ortega, J.J. Neuroimaging in pediatric leukemia and lymphoma: Differential diagnosis. *Radiographics 2002*, *22*, 1411–1428. [CrossRef] [PubMed]

106. Prakash, G.; Thulkar, S.; Arava, S.K.; Bakhshi, S. Cerebral Aspergillus infection in pediatric acute lymphoblastic leukemia induction therapy. *Indian J. Med. Paediatr. Oncol. 2012*, *33*, 236–238. [PubMed]

107. Czaja, A.S.; Reiter, P.D.; Schultz, M.L.; Valuck, R.J. Patterns of off-label prescribing in the pediatric intensive care unit and prioritizing future research. *J. Pediatr. Pharmacol. Ther.* 2015, *20*, 186–196. [PubMed]

108. Sunakawa, K.; Tsukimoto, I.; Tsunematsu, Y.; Honda, M.; Iwai, N.; Maniwa, T.; Haigo, H.; Suzuki, K.; Mori, T. Evaluation of the safety and efficacy of liposomal amphotericin B (L-AMB) in children. *J. Infect. Chemother.* 2009, *15*, 368–374. [CrossRef] [PubMed]

109. Kolve, H.; Ahlke, E.; Fegeler, W.; Ritter, J.; Jürgens, H.; Groll, A.H. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation. *J. Antimicrob. Chemother.* 2009, *64*, 383–387. [CrossRef] [PubMed]

110. Wiley, J.M.; Seibel, N.L.; Walsh, T.J. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. *Pediatr. Infect. Dis. J.* 2005, *24*, 167–174. [CrossRef] [PubMed]

111. Walsh, T.J.; Seibel, N.L.; Arndt, C.; Harris, R.E.; Dinubile, M.J.; Reboli, A.; Hiemenz, J.; Chanock, S.J. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. *Pediatr. Infect. Dis. J.* 1999, *18*, 702–708. [CrossRef] [PubMed]

112. Sandler, E.S.; Mustafa, M.M.; Tkaciewski, I.; Graham, M.L.; Morrison, V.A.; Green, M.; Trigg, M.; Abboud, M.; Aquino, V.M.; Gurwith, M.; et al. Use of amphotericin B colloidal dispersion in children. *J. Pediatr. Hematol. Oncol.* 2000, *22*, 242–246. [CrossRef] [PubMed]

113. Walsh, T.J.; Karlsson, M.O.; Driscoll, T.; Arguedas, A.G.; Adamson, P.; Saez-llorens, X.; Vora, A.J.; Arrieta, A.C.; Blumer, J.; Lutsar, I.; et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. *Antimicrob. Agents Chemother.* 2004, *48*, 2166–2172. [CrossRef] [PubMed]

114. Karlsson, M.O.; Lutsar, I.; Milligan, P.A. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. *Antimicrob. Agents Chemother.* 2009, *53*, 935–944. [CrossRef] [PubMed]
115. Walsh, T.J.; Driscoll, T.; Milligan, P.A.; Wood, N.D.; Schlamm, H.; Groll, A.H.; Jafri, H.; Arrieta, A.C.; Klein, N.J.; Lutsar, I. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. *Antimicrob. Agents Chemother.* 2010, 54, 4116–4123. [CrossRef] [PubMed]

116. Driscoll, T.A.; Yu, L.C.; Frangoul, H.; Robert, A.; Nemecek, E.; Blumer, J.; Arrieta, A.; Graham, M.L.; Bradfield, S.M.; Baruch, A.; Krance, R.A. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. *Antimicrob. Agents Chemother.* 2011, 55, 5770–5779. [CrossRef] [PubMed]

117. Friberg, L.E.; Ravva, P.; Karlsson, M.O.; Liu, P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. *Antimicrob. Agents Chemother.* 2012, 56, 3032–3042. [CrossRef] [PubMed]

118. Walsh, T.J.; Lutsar, I.; Driscoll, T.; Dupont, B.; Roden, M.; Ghahramani, P.; Hodges, M.; Groll, A.H.; Perfect, J.R. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. *Pediatr. Infect. Dis. J.* 2002, 21, 240–248. [CrossRef] [PubMed]

119. Herbrecht, R.; Denning, D.W.; Patterson, T.F.; Bennett, J.E.; Greene, R.E.; Oestmann, J.W.; Kern, W.V.; Marr, K.A.; Ribaud, P.; Lortholary, O.; et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N. Engl. J. Med.* 2002, 347, 408–415. [CrossRef] [PubMed]

120. De Repentigny, L.; Ratelle, J.; Leclerc, J.M.; Cornu, G.; Sokal, E.M.; Jacqmin, P.; De Beule, K. Repeated dose pharmacokinetics of an oral solution of itraconazole in infants and children. *Antimicrob. Agents Chemother.* 1998, 42, 404–408. [PubMed]

121. Krishna, G.; Sansone-Parsons, A.; Martinho, M.; Kantesaria, B.; Pedicone, L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. *Antimicrob. Agents Chemother.* 2007, 51, 812–818. [CrossRef] [PubMed]

122. Döring, M.; Müller, C.; Johann, P.D.; Erbacher, A.; Kimmig, A.; Schwarze, C.P.; Lang, P.; Handgretinger, R.; Müller, I. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. *BMC Infect. Dis.* 2012, 12, 263. [CrossRef] [PubMed]

123. Bernardo, V.A.; Cross, S.J.; Crews, K.R.; Flynn, P.M.; Hoffman, J.M.; Knapp, K.M.; Pauley, J.L.; Molinelli, A.R.; Greene, W.L. Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. *Ann. Pharmacother.* 2013, 47, 976–983. [CrossRef] [PubMed]

124. Döring, M.; Eikemeier, M.; Canavillas Stanchi, K.M.; Hartmann, U.; Ebinger, M.; Schwarze, C.P.; Schulz, A.; Handgretinger, R.; Müller, I. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia. *Eur. J. Clin. Microbiol. Infect. Dis.* 2015, 34, 1189–1200. [CrossRef] [PubMed]

125. Lehrnbecher, T.; Attarbaschi, A.; Duerken, M.; Garbino, J.; Gruhn, B.; Kontry, N.; Lüer, S.; Phillips, R.; Scholz, J.; Wagner, H.J.; et al. Posaconazole salvage treatment in paediatric patients: A multicentre survey. *Eur. J. Clin. Microbiol. Infect. Dis.* 2010, 29, 1043–1045. [CrossRef] [PubMed]

126. Walsh, T.J.; Adamson, P.C.; Seibell, N.L.; Flynn, M.; Neely, M.N.; Schwartz, C.; Shad, A.; Kaplan, S.L.; Roden, M.M.; Stone, J.A.; et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. *Antimicrob. Agents Chemother.* 2005, 49, 4536–4545. [CrossRef] [PubMed]

127. Neely, M.; Jafri, H.S.; Seibell, N.; Knapp, K.; Adamson, P.C.; Bradshaw, S.K.; Strohmaier, K.M.; Sun, P.; Bi, S.; Dockendorf, M.F.; et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. *Antimicrob. Agents Chemother.* 2009, 53, 1450–1456. [CrossRef] [PubMed]

128. Zaoutis, T.; Lehrnbecher, T.; Groll, A.H.; Steinbach, W.J.; Jafri, H.S.; Maertens, J.; Ngai, A.L.; Chow, J.W.; Taylor, A.F.; Strohmaier, K.M.; et al. Safety experience with caspofungin in pediatric patients. *Pediatr. Infect. Dis. J.* 2009, 28, 1132–1135. [CrossRef] [PubMed]

129. Li, C.; Sun, P.; Dong, Y.; Bi, S.; Desai, R.; Dockendorf, M.F.; Kartsonis, N.A.; Ngai, A.L.; Bradshaw, S.; Stone, J.A. Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients. *Antimicrob. Agents Chemother.* 2011, 55, 2098–2105. [CrossRef] [PubMed]

130. Groll, A.H.; Attarbaschi, A.; Schuster, F.R.; Herzog, N.; Grigull, L.; Dworzak, M.N.; Beutel, K.; Laws, H.J.; Lehrnbecher, T. Treatment with caspofungin in immunocompromised paediatric patients: A multicentre survey. *J. Antimicrob. Chemother.* 2006, 57, 527–535. [CrossRef] [PubMed]
131. Zaoutis, T.E.; Jafri, H.S.; Huang, L.M.; Locatelli, F.; Barzilai, A.; Ebell, W.; Steinbach, W.J.; Bradley, J.; Lieberman, J.M.; Hsiao, C.C.; et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. *Pediatrics* 2009, 123, 877–884. [CrossRef] [PubMed]

132. Seibel, N.L.; Schwartz, C.; Arrieta, A.; Flynn, P.; Shad, A.; Albano, E.; Keirns, J.; Lau, W.M.; Facklam, D.P.; Buell, D.N.; et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. *Antimicrob. Agents Chemother.* 2005, 49, 3317–3324. [CrossRef] [PubMed]

133. Hope, W.W.; Seibel, N.L.; Schwartz, C.; Arrieta, A.; Flynn, P.; Shad, A.; Albano, E.; Keirns, J.J.; Buell, D.N.; Gumbo, T.; et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. *Antimicrob. Agents Chemother.* 2007, 51, 3714–3719. [CrossRef] [PubMed]

134. Arrieta, A.C.; Maddison, P.; Groll, A.H. Safety of micafungin in pediatric clinical trials. *Pediatr. Infect. Dis. J.* 2011, 30, e97–e102. [CrossRef] [PubMed]

135. Hope, W.W.; Kaibara, A.; Roy, M.; Arrieta, A.; Azie, N.; Kovanda, L.L.; Benjamin, D.K., Jr. Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents. *Antimicrob. Agents Chemother.* 2015, 59, 905–913. [CrossRef] [PubMed]

136. Denning, D.W.; Marr, K.A.; Lau, W.M.; Facklam, D.P.; Ratanatharathorn, V.; Becker, C.; Ullmann, A.J.; Seibel, N.L.; Flynn, P.M.; van Burik, J.A.H.; et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. *J. Infect.* 2006, 53, 337–349. [CrossRef] [PubMed]

137. Benjamin, D.K., Jr.; Driscoll, T.; Seibel, N.L.; Gonzalez, C.E.; Roden, M.M.; Kilaru, R.; Clark, K.; Dowell, J.A.; Schranz, J.; Walsh, T.J. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. *Antimicrob. Agents Chemother.* 2006, 50, 632–638. [CrossRef] [PubMed]

138. Walsh, T.J.; Anaissie, E.J.; Denning, D.W.; Herbrecht, R.; Kontoyiannis, D.P.; Marr, K.A.; Morrison, V.A.; Segal, B.H.; Steinbach, W.J.; Stevens, D.A.; et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. *Clin. Infect. Dis.* 2008, 46, 327–360. [CrossRef] [PubMed]

139. Groll, A.H.; Castagnola, E.; Cesaro, S.; Dalle, J.H.; Engelhard, D.; Hope, W.; Rolildes, E.; Styczynski, J.; Warris, A.; Lehrnbecher, T. Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. *Lancet Oncol.* 2014, 15, e327–e340. [CrossRef]

140. Steinbach, W.J.; Perfect, J.R.; Schell, W.A.; Walsh, T.J.; Benjamin, D.K., Jr. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. *Antimicrob. Agents Chemother.* 2004, 48, 3217–3225. [CrossRef] [PubMed]

141. Hamill, R.J. Amphotericin B formulations: A comparative review of efficacy and toxicity. *Drugs* 2013, 73, 919–934. [CrossRef] [PubMed]

142. Groll, A.H.; Giri, N.; Petrakis, V.; Petratiene, R.; Candelario, M.; Bacher, J.S.; Piscitelli, S.C.; Walsh, T.J. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental *Candida albicans* infection of the central nervous system. *J. Infect. Dis.* 2000, 182, 274–282. [CrossRef]

143. Manavathu, E.K.; Cutright, J.L.; Chandrasekar, P.H. Organism-dependent fungicidal activities of azoles. *Antimicrob. Agents Chemother.* 1998, 42, 3018–3021. [PubMed]

144. Zane, N.R.; Thakker, D.R. A physiologically based pharmacokinetic model for voriconazole disposition predicts intestinal first-pass metabolism in children. *Clin. Pharmacokinet.* 2014, 53, 1171–1182. [CrossRef] [PubMed]

145. Bartelink, I.H.; Wolfs, T.; Jonker, M.; De Waal, M.; Egberts, T.C.; Ververs, T.T.; Boelens, J.J.; Bierings, M. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. *Antimicrob. Agents Chemother.* 2013, 57, 235–240. [CrossRef] [PubMed]

146. Neely, M.; Rushing, T.; Kovacs, A.; Jelliffe, R.; Hoffman, J. Voriconazole pharmacokinetics and pharmacodynamics in children. *Clin. Infect. Dis.* 2010, 50, 27–36. [CrossRef] [PubMed]

147. Troke, P.F.; Hockey, H.P.; Hope, W.W. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. *Antimicrob. Agents Chemother.* 2011, 55, 4782–4788. [CrossRef] [PubMed]
148. Choi, S.; Lee, S.; Hwang, J.; Lee, S.; Yoo, K.; Sung, K.; Koo, H.; Kim, Y. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. *Pediatr. Blood Cancer* 2013, 60, 82–87. [CrossRef] [PubMed]

149. Kang, H.M.; Lee, H.J.; Cho, E.Y.; Yu, K.-S.; Lee, H.; Lee, J.W.; Kang, H.J.; Park, K.D.; Shin, H.Y.; Choi, E.H. The clinical significance of voriconazole therapeutic drug monitoring in children with invasive fungal infections. *Pediatr. Hematol. Oncol.* 2013, 30, 557–567. [CrossRef] [PubMed]

150. Luong, M.-L.; Al-Dabbagh, M.; Groll, A.H.; Racil, Z.; Nannya, Y.; Mitsani, D.; Husain, S. Utility of voriconazole therapeutic drug monitoring: A meta-analysis. *J. Antimicrob. Chemother.* 2016. [CrossRef]

151. Park, W.B.; Kim, N.H.; Kim, K.H.; Lee, S.H.; Nam, W.S.; Yoon, S.H.; Song, K.H.; Choe, P.G.; Kim, N.J.; Jang, I.J.; et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: A randomized controlled trial. *Clin. Infect. Dis.* 2012, 55, 1080–1087. [CrossRef] [PubMed]

152. Aypar, E.; Kendirli, T.; Tutar, E.; Ciftçi, E.; Ince, E.; Ileri, T.; Atalay, S. Voriconazole-induced QT interval prolongation and torsades de pointes. *Pediatr. Int.* 2011, 53, 761–763. [CrossRef] [PubMed]

153. Bernhard, S.; Kernland Lang, K.; Ammann, R.A.; Lüer, S.; Leibundgut, K.; Diepold, M.; Aebi, C. Voriconazole-induced phototoxicity in children. *Pediatr. Infect. Dis. J.* 2012, 31, 769–771. [CrossRef] [PubMed]

154. Van Hasselt, J.G.; Van Eijkelenburg, N.K.; Huitema, A.D.; Schellens, J.H.; Schouten-van Meeteren, A.Y. Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate. *Antimicrob. Agents Chemother.* 2013, 57, 2878–2881. [CrossRef] [PubMed]

155. Cowen, E.W.; Nguyen, J.C.; Miller, D.D.; McShane, D.; Arron, S.T.; Prose, N.S.; Turner, M.L.; Fox, L.P. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. *J. Am. Acad. Dermatol.* 2010, 62, 31–37. [CrossRef] [PubMed]

156. Wermers, R.A.; Cooper, K.; Razonable, R.R.; Deziel, P.; Whitford, G.M.; Kremers, W.K.; Moyer, T.P. Fluoride excess and periostitis in pediatric hematopoietic stem cell transplant recipients receiving long-term voriconazole therapy. *Pediatr. Blood Cancer* 2015, 62, 918–920. [CrossRef] [PubMed]

157. Tarlock, K.; Johnson, D.; Cornell, C.; Parnell, S.; Meshinchi, S.; Baker, K.; Englund, J. Elevated fluoride levels and periostitis in pediatric hematopoietic stem cell transplant recipients receiving long-term voriconazole. *Pediatr. Blood Cancer* 2015, 62, 918–920. [CrossRef] [PubMed]

158. Maertens, J.A.; Raad, I.I.; Marr, K.A.; Patterson, T.F.; Contoyiannis, D.P.; Cornely, O.A.; Bow, E.J.; Rahav, G.; Nix, D.E.; Peloquin, C.A.; Graham, M.L. Poor absorption of high-dose posaconazole in pediatric bone marrow transplant patients. *Ann. Pharmacother.* 2012, 46, e22. [CrossRef] [PubMed]

159. Merck Sharp & Dohme Corp. A study of the safety, tolerance, and pharmacokinetics of oral posaconazole in immunocompromised children. In ClinicalTrials.gov. Bethesda(MD): National Library of Medicine (US). Available online: https://clinicaltrials.gov/ct2/show/results/NCT01716234?NLMIdentifier=NCT01716234 (accessed on 1 April 2016).

160. Miceli, M.H.; Kauffman, C.A. Isavuconazole: A new broad-spectrum triazole antifungal agent. *Clin. Infect. Dis.* 2015, 61, 1558–1565. [CrossRef] [PubMed]

161. Marr, K.A.; Schlamm, H.T.; Herbrecht, R.; Rottinghaus, S.T.; Bow, E.J.; Cornely, O.A.; Heinz, W.J.; Jagannatha, S.; Koh, L.P.; Contoyiannis, D.P.; et al. Combination antifungal therapy for invasive aspergillosis a randomized trial. *Ann. Intern. Med.* 2015, 162, 81–89. [CrossRef] [PubMed]
164. Perruccio, K.; Tosti, A.; Burchielli, E.; Topini, F.; Ruggeri, L.; Carotti, A.; Capanni, M.; Urbani, E.; Mancusi, A.; Aversa, F.; et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. **Blood** **2005**, **106**, 4397–4406. [CrossRef] [PubMed]

165. Papadopoulou, A.; Kaloyannidis, P.; Yannaki, E.; Cruz, C.R. Adoptive transfer of *Aspergillus*-specific T cells as a novel anti-fungal therapy for hematopoietic stem cell transplant recipients: Progress and challenges. **Crit. Rev. Oncol. Hematol.** **2016**, **98**, 62–72. [CrossRef] [PubMed]

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).